Runben Biotechnology (SH:603193) Hua Yuan Zheng Quan·2025-07-23 07:11Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is expected to benefit from the synergy in the mosquito repellent and baby care segments, with a comprehensive channel layout expanding performance potential [5] - The company has launched over 90 new products in 2024, catering to differentiated consumer needs, which is anticipated to drive revenue growth [8] - The company has established a strong brand image in the domestic market and is expected to maintain high growth through a refined brand matrix and competitive pricing strategy [8] Financial Performance Summary - Revenue projections for the company are as follows: - 2023: 1,033 million RMB - 2024: 1,318 million RMB (YoY growth of 27.61%) - 2025: 1,771 million RMB (YoY growth of 34.33%) - 2026: 2,246 million RMB (YoY growth of 26.84%) - 2027: 2,759 million RMB (YoY growth of 22.84%) [7] - Net profit projections are as follows: - 2023: 226 million RMB - 2024: 300 million RMB (YoY growth of 32.80%) - 2025: 389 million RMB (YoY growth of 29.45%) - 2026: 490 million RMB (YoY growth of 25.99%) - 2027: 605 million RMB (YoY growth of 23.61%) [7] - Earnings per share (EPS) projections are: - 2023: 0.56 RMB - 2024: 0.74 RMB - 2025: 0.96 RMB - 2026: 1.21 RMB - 2027: 1.50 RMB [7] Market Data - As of July 22, 2025, the closing price of the stock is 29.63 RMB, with a market capitalization of 11,988.10 million RMB and a circulating market value of 3,061.85 million RMB [3] - The company's asset-liability ratio stands at 7.69% and the net asset value per share is 5.25 RMB [3]